CHEK2 and invasive breast carcinoma: When we compare our cases to 21,384 non-Finnish European controls from gnomAD (gnomAD controls v2.1, http://gnomad.broadinstitute.org), we see that the odds ratios fall to similar levels previously reported for invasive cancer with the exception of CHEK2 (OR = 3.69, 95%CI.19–6.23) which still remains higher than that reported in studies of invasive breast cancer (OR~ 2), Table 2.